You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 8,029,791

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,029,791

Title:	Modified chimeric polypeptides with improved pharmacokinetic properties
Abstract:	Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
Inventor(s):	Papadopoulos; Nicholas J. (LaGrangeville, NY), Davis; Samuel (New York, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	12/102,666
Patent Claims:	1. A dimeric vascular endothelial growth factor (VEGF) antagonist, comprising two fusion proteins, each fusion protein consisting of (a) a VEGF receptor component having immunoglobulin-like (Ig) domains consisting of an Ig domain 2 of a first VEGF receptor human Flt1 and Ig domain 3 of a second VEGF receptor human Flk1; and (b) a multimerizing component. 2. The dimeric VEGF antagonist of claim 1, wherein the multimerizing component comprises an immunoglobulin domain. 3. The dimeric VEGF antagonist of claim 2, wherein the immunoglobulin domain is chosen from the Fc domain of IgG and the heavy chain of IgG. 4. The dimeric VEGF antagonist of claim 3, wherein each fusion protein comprises amino acids 27-458 of the amino acid sequence shown in SEQ ID NO:16. 5. A dimeric vascular endothelial growth factor (VEGF) antagonist, comprising two fusion proteins, each fusion protein consisting of (a) a VEGF receptor component having immunoglobulin-like (Ig) domains consisting of an Ig domain 2 of a first VEGF receptor human Flt1 and Ig domain 3 of a second VEGF receptor human Flk1; and (b) an Fc domain of IgG. 6. A composition comprising a VEGF antagonist and a carrier, wherein the VEGF antagonist comprises two fusion proteins, each fusion protein consisting of (a) a VEGF receptor component having immunoglobulin-like (Ig) domains consisting of an Ig domain 2 of a first VEGF receptor human Flt1 and Ig domain 3 of a second VEGF receptor human Flk1; and (b) a multimerizing component. 7. The composition of claim 6, wherein the multimerizing component comprises an immunoglobulin domain. 8. The composition of claim 7, wherein the immunoglobulin domain is an Fc domain of IgG. 9. The composition of claim 8, wherein each fusion protein comprises amino acids 27-458 of the amino acid sequence of SEQ ID NO:16.

Details for Patent 8,029,791

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	11/18/2011	⤷ Try a Trial	2019-06-08
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	08/16/2018	⤷ Try a Trial	2019-06-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,029,791

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Argentina	044938	⤷ Try a Trial
Austria	293164	⤷ Try a Trial
Austria	417928	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.